An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of abacavir 600 mg/lamivudine 300 mg once-daily in combination with atazanavir 300 mg + ritonavir 100 mg once-daily in antiretroviral-naive HIV-1 infected subjects with continuing evaluation of abacavir/lamivudine plus atazanavir 400 mg for maintenance over an additional 48 weeks

Trial Profile

An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of abacavir 600 mg/lamivudine 300 mg once-daily in combination with atazanavir 300 mg + ritonavir 100 mg once-daily in antiretroviral-naive HIV-1 infected subjects with continuing evaluation of abacavir/lamivudine plus atazanavir 400 mg for maintenance over an additional 48 weeks

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Atazanavir (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SHARE
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top